IRX Therapeutics Enters Research Collaboration


IRX Therapeutics has signed a research collaboration agreement with a leading research-based pharmaceutical company to assess the potential effects of IRX-2 on the tumor microenvironment. Tumor specimens from subjects treated with IRX-2 and control subjects will be analyzed using gene analysis technology to characterize the action of IRX-2 immunotherapy at the molecular level.

IRX-2 is designed to broadly restore the immune system to overcome cancer–induced immune suppression and restore anti-tumor response. The IRX-2 immunomodulator includes multiple cytokine components that work to activate different arms of the immune system. IRX Therapeutics performed a Phase II trial that enrolled patients with newly diagnosed head and neck squamous cell cancer who received IRX-2 immunotherapy prior to surgery.

“This is a great opportunity for IRX Therapeutics to work with one of the leading developers of cancer therapies to further our understanding of the action of our novel immunomodulator, IRX-2. We are hopeful that these studies will further evidence the potential of IRX-2 to effect an immune based attack on a cancer patient’s tumor,” said John W. Hadden II, president and chief executive officer of IRX Therapeutics.